ESTRO 2024 - Abstract Book

S248

Brachytherapy - Gynaecology

ESTRO 2024

Survival and disease control outcome based on treatment type is shown in table 1.

Table 1: Outcome based on the treatment type

IGABT alone (n=15)

EBRT + IGABT (n=31)

Median age years (range)

69 (57-85)

68(48-84)

Median time to vaginal recurrence (months) 21

19

Median follow up for survival (months) 90

53

5 year actuarial OS %

78.0

72.0

Median follow up for disease control (months) 50

40

Actuarial LC @ 2 and 5 years %

100/87.5

96.3/96.3

Actuarial LRC @ 2 and 5 years %

100/78.8

93.1/88.2

Actuarial DC @ 2 and 5 years %

92.9/92.9

83.9/76.5

OS after 2/5 years was 94.6%/80.6% for radiotherapy naïve patients and 88.9%/44.4% for patients with previous pelvic irradiation.

Overall, nine patients experienced grade 3 toxicities (fistula n=2, urinary incontinence n=1, vaginal stricture n=7, vaginal necrosis n=1; multiple events per patient possible). There were no G4 and G5 toxicities. The two patients with vesico-vaginal and/or vesico-enteral fistula had received reirradiation for vaginal recurrence after EBRT+BT as treatment at initial diagnosis. In addition, there were two further patients with vaginal necrosis (G2) persisting for less than six months under conservative management.

Conclusion:

Radiotherapy is an effective salvage treatment for vaginal recurrences of endometrial cancer. Small, superficial tumors can be treated with IGABT alone, while more advanced tumors can be successfully salvaged with a combination of EBRT + IGABT with acceptable toxicity rates.

Keywords: IGABT, recurrent endometrial cancer

1127

Digital Poster

Analysis of interstitial catheter number and dosimetric parameters in cervical cancer brachytherapy